Literature DB >> 32380462

Disparities in the Use of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma.

Jordan M Cloyd1, Chengli Shen1, Heena Santry1, John Bridges1, Mary Dillhoff1, Aslam Ejaz1, Timothy M Pawlik1, Allan Tsung1.   

Abstract

BACKGROUND: Current guidelines support either immediate surgical resection or neoadjuvant therapy (NT) for patients with resectable pancreatic ductal adenocarcinoma (PDAC). However, which patients are selected for NT and whether disparities exist in the use of NT for PDAC are not well understood.
METHODS: Using the National Cancer Database from 2004 through 2016, the clinical, demographic, socioeconomic, and hospital-related characteristics of patients with stage I/II PDAC who underwent immediate surgery versus NT followed by surgery were compared.
RESULTS: Among 58,124 patients who underwent pancreatectomy, 8,124 (14.0%) received NT whereas 50,000 (86.0%) did not. Use of NT increased significantly throughout the study period (from 3.5% in 2004 to 26.4% in 2016). Multivariable logistic regression analysis showed that travel distance, education level, hospital facility type, clinical T stage, tumor size, and year of diagnosis were associated with increased use of NT, whereas comorbidities, uninsured/Medicaid status, South/West geography, left-sided tumor location, and increasing age were associated with immediate surgery (all P<.001). Based on logistic regression-derived interaction factors, the association between NT use and median income, education level, Midwest location, clinical T stage, and clinical N stage significantly increased over time (all P<.01).
CONCLUSIONS: In addition to traditional clinicopathologic factors, several demographic, socioeconomic, and hospital-related factors are associated with use of NT for PDAC. Because NT is used increasingly for PDAC, efforts to reduce disparities will be critical in improving outcomes for all patients with pancreatic cancer.

Entities:  

Mesh:

Year:  2020        PMID: 32380462     DOI: 10.6004/jnccn.2019.7380

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  11 in total

1.  Age-related Survival Outcomes for Pancreatic Cancer by Age.

Authors:  Ali Abbaszadeh Kasbi; Mohammed Ali Ashary; Mizba Baksh; Samuel Nussbaum; Kristopher Attwood; Emmanuel Gabriel
Journal:  Cancer Diagn Progn       Date:  2022-01-03

2.  Association of social determinants of health with late diagnosis and survival of patients with pancreatic cancer.

Authors:  Jesus C Fabregas; Kristen E Riley; Jeannine M Brant; Thomas J George; E John Orav; Miranda B Lam
Journal:  J Gastrointest Oncol       Date:  2022-06

3.  Characterizing the patient experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma: A qualitative study.

Authors:  Lena Stevens; Zachary J Brown; Ryan Zeh; Christina Monsour; Sharla Wells-Di Gregorio; Heena Santry; Aslam M Ejaz; Timothy Michael Pawlik; Jordan M Cloyd
Journal:  World J Gastrointest Oncol       Date:  2022-06-15

4.  Impact of care fragmentation on the outcomes of patients receiving neoadjuvant and adjuvant therapy for pancreatic adenocarcinoma.

Authors:  Zachary J Brown; Hanna E Labiner; Chengli Shen; Aslam Ejaz; Timothy M Pawlik; Jordan M Cloyd
Journal:  J Surg Oncol       Date:  2021-10-02       Impact factor: 2.885

5.  Multi-specialty physician perspectives on barriers and facilitators to the use of neoadjuvant therapy for pancreatic ductal adenocarcinoma.

Authors:  Lena Schreiber; Ryan Zeh; Christina Monsour; Aslam Ejaz; Allan Tsung; Timothy M Pawlik; Eric Miller; Anne Noonan; Somashekar G Krishna; Heena Santry; Jordan M Cloyd
Journal:  HPB (Oxford)       Date:  2021-10-25       Impact factor: 3.842

6.  Disparities in Access to Oncologic Care in Pancreatic Cancer: A Systematic Review.

Authors:  Annabelle L Fonseca; Hamza Khan; Krista R Mehari; Deepa Cherla; Martin J Heslin; Fabian M Johnston
Journal:  Ann Surg Oncol       Date:  2022-01-23       Impact factor: 5.344

7.  Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Jordan M Cloyd; Victor Heh; Timothy M Pawlik; Aslam Ejaz; Mary Dillhoff; Allan Tsung; Terence Williams; Laith Abushahin; John F P Bridges; Heena Santry
Journal:  J Clin Med       Date:  2020-04-15       Impact factor: 4.241

8.  Concepts and Outcomes of Perioperative Therapy in Stage IA-III Pancreatic Cancer-A Cross-Validation of the National Cancer Database (NCDB) and the German Cancer Registry Group of the Society of German Tumor Centers (GCRG/ADT).

Authors:  Louisa Bolm; Sergii Zemskov; Maria Zeller; Taisuke Baba; Jorge Roldan; Jon M Harrison; Natalie Petruch; Hiroki Sato; Ekaterina Petrova; Hryhoriy Lapshyn; Ruediger Braun; Kim C Honselmann; Richard Hummel; Oleksii Dronov; Alexander V Kirichenko; Monika Klinkhammer-Schalke; Kees Kleihues-van Tol; Sylke R Zeissig; Dirk Rades; Tobias Keck; Carlos Fernandez-Del Castillo; Ulrich F Wellner; Rodney E Wegner
Journal:  Cancers (Basel)       Date:  2022-02-09       Impact factor: 6.639

Review 9.  Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.

Authors:  Megan L Sulciner; Stanley W Ashley; George Molina
Journal:  J Clin Med       Date:  2022-08-19       Impact factor: 4.964

Review 10.  Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma.

Authors:  Clifford Akateh; Aslam M Ejaz; Timothy Michael Pawlik; Jordan M Cloyd
Journal:  World J Hepatol       Date:  2020-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.